Carissa Benedict
Medical · Colorado Springs, CONPI 1417112848
Payments from drug & device makers
Across 270 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$893
- Pfizer$473
- Takeda Pharmaceuticals U.S.A., Inc.$439
- Lilly USA, LLC$366
- Novo Nordisk$360
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,50299%
- Education$721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,574 in reported general payments places this provider in the 90th percentile of 766 medical providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 61 | $71,904 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $34,149 |
| OzempicSemaglutide | 30 | $34,130 |
| ProliaDenosumab | 12 | $21,087 |
| FarxigaDapagliflozin Propanediol | 15 | $19,984 |
| XareltoRivaroxaban | 19 | $14,757 |
| Nurtec OdtRimegepant Sulfate | 15 | $14,575 |
| MyrbetriqMirabegron | 11 | $12,887 |
| Rosuvastatin Calcium | 147 | $1,564 |
| Levothyroxine Sodium | 140 | $1,094 |
| Omeprazole | 66 | $1,070 |
| Gabapentin | 35 | $785 |
| Duloxetine Hcl | 23 | $655 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $653 |
| Quetiapine Fumarate | 19 | $648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $366 | $71,90461 claims |
| GSKTrelegy Ellipta | $89 | $34,14926 claims |
| Novo NordiskOzempic | $360 | $34,13030 claims |
| AmgenProlia | $358 | $21,08712 claims |
| AstraZenecaFarxiga | $893 | $19,98415 claims |
| Johnson & JohnsonXarelto | $22 | $14,75719 claims |
| PfizerNurtec Odt | $473 | $14,57515 claims |
| Astellas Pharma US IncMyrbetriq | $164 | $12,88711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 766 medical providers in Colorado.
Other medical in Colorado Springs
- Christen KutzColorado Springs$2.4M
- Kristin RyggColorado Springs$255K
- Michelle BarnettColorado Springs$138K
- Deanna JohnsonColorado Springs$41K
- David BrunkColorado Springs$18K
- Meghan CogswellColorado Springs$18K
- Amanda MixonFort Collins$342K
- Jordan MastDenver$247K
- John NovakAurora$173K
- Michael JacobsonFort Collins$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.